Ipsen is an innovation-driven international specialty pharmaceutical group with drugs marketed in 115 countries and a total worldwide staff of nearly 4,600.

Its development strategy is based on a combination of specialty products, which are growth drivers, in targeted therapeutic areas (oncology, endocrinology and neurology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 900 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2013, Research and Development expenditure was about €260 million, more than 21% of consolidated sales, which exceeded €1.2 billion.

For more information on Ipsen, visit our website at www.ipsen.com.